FCS and SHTG: Are We Meeting the Need?
Ira J. Goldberg, MD
Kausik Ray, MBChB, MD, MPhil
Christie Ballantyne, MD
Clinical choices in managing LDL-c: Where do novel therapies fit in?
Julia Brandts, MD
Pasquale Perrone-Filardi, MD, PhD
Ulrich Laufs, MD, PhD
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
Reaching LDL-c targets in patients at high CV risk: How well are we doing?
The remaining challenges in lowering LDL-c in patients at increased CV risk
Prof. Kausik Ray
Understanding the role of triglycerides in the assessment of residual risk
Prof. Alberto Zambon MD, PhD, FAHA
Managing a patient with residual risk: Applying recent evidence with EPA to practice
Innovating the clinical management of LDL-c: Exploring CETP as therapeutic target
John Kastelein, MD, PhD
Stephen Nicholls, FRACP, FACC, FESC, FAHA
Erin Michos
Clinical scenarios addressing residual risk in ASCVD: Understanding the role of triglycerides and EPA
Azfar Zaman, MD
A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?
CETP inhibition: Lessons from two decades of clinical trials
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
Integrating EPA in CV risk reduction strategies: Practical experience and guidance
ACC 2024: SHASTA-2 Final Study Results
Daniel Gaudet, MD, PhD
Plozasiran (ARO-APOC3) Decreases APOC3 and Triglycerides (TG) in Patients With Mixed Hyperlipidemia: MUIR Final Results
Loading...
We're glad to see you're enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.